Anaplastic thyroid cancer: All anaplastic thyroid cancers will begin at stage IV, which is why this type of thyroid cancer usually receives a poor prognosis. Recurrent cancer: ...

Anaplastic thyroid cancer has historically had very poor prognoses, with nearly 100% of cases being fatal. In stage IVB, the current standard of care has involved multimodal therapy, including ...

Atezolizumab combined with targeted therapy improved median overall survival to 19 months in patients with anaplastic thyroid carcinoma (ATC). The longest survival was observed in the BRAF V600E ...

The mixed-cohort trial of patients with advanced thyroid cancers, reported by Kartik Sehgal, MD, of Dana-Farber Cancer Institute in Boston, and colleagues, included 51 patients, with 49 evaluable ...

Its lead candidate, AIC100, is currently in a Phase 1 study to treat patients with advanced thyroid cancers including advanced differentiated thyroid cancer (ADTC) and anaplastic thyroid cancer (ATC).

About c-MYC c-MYC is a well-validated oncogene with broad anti-cancer potential, as c-MYC expression is dysregulated in more than 70% of cancers and a key regulator in nearly every aspect of ...

The potentially promising early results in anaplastic thyroid cancer (ATC) and relapsed/refractory poorly differentiated thyroid cancer (PTDC) – which have limited treatment options and poor ...